Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

Assiut University

ClinicalTrials.gov lists Assiut University as lead sponsor of 5,010 trials. It has 638 active development programs and 399 approved assets.

EG Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

630 0 2000 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 627 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 610 in 2026 and about 630 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (500 or more), forecasts made part-way through the year were typically off by about 15 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 25 percent and ran about 15 percent low against the count later registered, and had about 7 percent more error than repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 627 already registered with a 2026 start date: at the cutoff, 176 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts. 6 trials are registered to start in 2027 or later.

This page covers Assiut University: 5,010 lead-sponsored trials and 1 legal-entity registration.

Get the Assiut University report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (979)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Pain 195
Postoperative Pain 101
Hemorrhage 100
Diabetes Mellitus 97
COVID-19 78

Trials by start year as sponsor or collaborator (22)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 627
2025 606
2024 630
2023 548
2022 419
2021 404
2020 423
2019 400
2018 379
2017 355

Prediction, not a registry value: median of 30 months from start to primary completion across 114 trials still running at the 2026-10-09 snapshot; registered median of 13 months across 915 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (638)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
DEXMEDETOMIDINE Delirium Phase 3 3
Acetaminophen Pain Phase 3 3
Intravenous Tranexamic Acid Hemorrhage Phase 3 3
DEXMEDETOMIDINE Emergence Delirium Phase 3 3
+/- Bupivacaine HCl Cleft Palate Phase 3 3

Approved assets (399)

Shown in this order: max phase first.

Approved assets
Drug Trials
DEXMEDETOMIDINE 78
+/- Bupivacaine HCl 51
DEXAMETHASONE 36
(R,S)-ketamine (Pilot I) 23
Lidocaine 19

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
76% hit target (n=530) 35% on time (n=524)

Journals published in (3,144)

Shown in this order: most published in first.

Journals published in
Journal Publications
Lancet (London, England) 168
The New England journal of medicine 151
PloS one 122
Circulation 98
Journal of the American College of Cardiology 84

Organization relationships (23)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
South Egypt Cancer Institute Co sponsors trial with 3
Sohag University Co sponsors trial with 2
Suez Canal University Co sponsors trial with 1
Cairo University Co sponsors trial with 1
King Saud University Co sponsors trial with 1

Latest dated events (5,090)

Shown in this order: newest first.

Latest dated events
Date Event Source
2027-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2027-06-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2027-06-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2027-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2027-01-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (961)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABL1 Trial sponsor Named in trial inclusion criteria
ABL1 Trial sponsor Named in trial inclusion criteria
ABO Trial sponsor Named in trial inclusion criteria
ABO Trial sponsor Named in trial inclusion criteria
ABR Trial sponsor Named in trial inclusion criteria

Biomarkers this organization publishes on (177)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
CRP 14
TNF 10
INS 9
ACE2 6
IL6 6

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.